Chronic kidney disease (CKD) affects up to 26 million Americans, or 13% of the United States population. Moderate-severe CKD (stage 3-4, defined by glomerular filtration rate 15-59 mL/min/1.73m2) has a particularly large public health impact because it is most prevalent and because it potently amplifies risk of cardiovascular disease. Specifically, individuals with moderate-severe CKD have important """"""""non-traditional"""""""" risk factors for cardiovascular disease which are not adequately addressed by risk reduction strategies developed for the general population. Insulin resistance is one """"""""non-traditional"""""""" mechanism through which CKD may cause cardiovascular disease. In CKD, post-receptor resistance to insulin action in skeletal muscle is commonly acquired due to unique metabolic abnormalities, including impaired renal calcitriol synthesis, metabolic acidosis, and accumulation of uremic toxins. In turn, insulin resistance may promote cardiovascular disease by impairing endothelial function, increasing reactive oxygen species, and exacerbating systemic inflammation. The metabolic abnormalities unique to CKD fundamentally alter the pathophysiology and ascertainment of insulin resistance and offer novel potential targets for therapeutic intervention. The overall goal of this grant application is to comprehensively characterize insulin resistance in moderate- severe CKD. First, we propose to define the severity of insulin resistance, the compensatory response of the pancreatic beta cell, and net effects on glucose tolerance, which are currently poorly understood, using gold standard methods (hyperinsulinemic euglycemic clamp, intravenous glucose tolerance test, oral glucose tolerance test). Second, we propose to develop and validate formulae estimating insulin resistance for use in future epidemiologic studies and clinical trials. Third, we propose to test associations of insulin resistance with endothelial function, oxidative stress, and inflammation. To accomplish these goals, we have assembled a multidisciplinary team with expertise in the biology of CKD, metabolism, quantitative assessment of insulin sensitivity and beta-cell function, nutrition, and biostatistics. As part of this innovative collaborative approach, this study will take advantage of existing resources at the University of Washington and the Kidney Research Institute in Seattle. These include the Institute for Translational Health Sciences Clinical Research Center, Nutrition and Body Composition Core, and Center for Biomedical Statistics.

Public Health Relevance

Moderate-severe CKD is an important public health problem due to its high prevalence and poor health outcomes. The key to improving long-term health outcomes in this population is prevention of cardiovascular disease. Persons with stage moderate-severe CKD are at high risk of cardiovascular events and are up to 11 times more likely to die, mostly due to cardiovascular disease, than to progress to kidney failure. Once completed, the proposed studies will provide a sound empirical basis to support the design of future large epidemiologic studies and clinical trials targeting insulin resistance in CKD. The ultimate goal of this work is to reduce the high morbidity and mortality in the large group of patients with moderate-severe CKD.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK087726-04
Application #
8516029
Study Section
Kidney, Nutrition, Obesity and Diabetes (KNOD)
Program Officer
Flessner, Michael Francis
Project Start
2010-08-15
Project End
2014-07-31
Budget Start
2013-08-01
Budget End
2014-07-31
Support Year
4
Fiscal Year
2013
Total Cost
$277,295
Indirect Cost
$99,542
Name
University of Washington
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195
Afkarian, Maryam; Zelnick, Leila R; Hall, Yoshio N et al. (2016) Clinical Manifestations of Kidney Disease Among US Adults With Diabetes, 1988-2014. JAMA 316:602-10
de Boer, Ian H; Gao, Xiaoyu; Cleary, Patricia A et al. (2016) Albuminuria Changes and Cardiovascular and Renal Outcomes in Type 1 Diabetes: The DCCT/EDIC Study. Clin J Am Soc Nephrol 11:1969-1977
Roshanravan, Baback; Kestenbaum, Bryan; Gamboa, Jorge et al. (2016) CKD and Muscle Mitochondrial Energetics. Am J Kidney Dis 68:658-9
Bowlby, Wilson; Zelnick, Leila R; Henry, Connor et al. (2016) Physical activity and metabolic health in chronic kidney disease: a cross-sectional study. BMC Nephrol 17:187
Ikizler, Halil O; Zelnick, Leila; Ruzinski, John et al. (2016) Dietary Acid Load is Associated With Serum Bicarbonate but not Insulin Sensitivity in Chronic Kidney Disease. J Ren Nutr 26:93-102
de Boer, Ian H; Afkarian, Maryam; Tuttle, Katherine R (2016) The Surging Tide of Diabetes: Implications for Nephrology. Am J Kidney Dis 67:364-6
Afkarian, Maryam; Katz, Ronit; Bansal, Nisha et al. (2016) Diabetes, Kidney Disease, and Cardiovascular Outcomes in the Jackson Heart Study. Clin J Am Soc Nephrol 11:1384-91
de Boer, Ian H; Zelnick, Leila; Afkarian, Maryam et al. (2016) Impaired Glucose and Insulin Homeostasis in Moderate-Severe CKD. J Am Soc Nephrol 27:2861-71
Afkarian, Maryam; Zelnick, Leila R; Ruzinski, John et al. (2015) Urine matrix metalloproteinase-7 and risk of kidney disease progression and mortality in type 2 diabetes. J Diabetes Complications 29:1024-31
de Boer, Ian H; Mehrotra, Rajnish (2014) Insulin resistance in chronic kidney disease: a step closer to effective evaluation and treatment. Kidney Int 86:243-5

Showing the most recent 10 out of 30 publications